



## **CUMBERLAND EMERGING TECHNOLOGIES ANNOUNCES NEW SMALL BUSINESS GRANT AWARD**

**NASHVILLE, Tenn. (November 14, 2016)** – **Cumberland Emerging Technologies, Inc. (CET)** today announced that the U.S. National Institutes of Health (NIH) has awarded \$225,000 in support of a joint research program involving *Cumberland Pharmaceuticals Inc.*, *Cumberland Emerging Technologies, Inc.*, and researchers at *Vanderbilt University*. This Phase I grant is awarded under the Small Business Technology Transfer Research (STTR) funding mechanism.

The objective of the collaborative research program is to advance development of a novel imaging agent to locate sites of internal bleeding. This technology addresses a significant unmet medical need for patients exhibiting clinical signs of internal bleeding. Current clinical test methods too often fail to locate the source of bleeding, complicating patients' clinical management plans.

Seth Karp M.D., Professor and Chairman of the Department of Surgery at Vanderbilt University Medical Center is Inventor of the technology. H. Charles Manning, Ph.D. is Principal Investigator of the NIH STTR Phase I grant. As Director of the Vanderbilt Center for Molecular Probes and Molecular Imaging Research, Dr. Manning will oversee testing of the imaging agent. Cumberland has also entered into a research agreement with Vanderbilt University Medical Center to provide funding and support for the collaborative research program headed by Dr. Karp and Dr. Manning, to achieve objectives proposed in the grant submission.

In addition to project management and grant administration, Cumberland is providing formulation, product development, and regulatory support to help advance this technology and create a new medical imaging drug product candidate for clinical use.

### **About Cumberland Emerging Technologies Inc.**

Cumberland Emerging Technologies, Inc. ([www.cet-fund.com](http://www.cet-fund.com)) is a joint initiative between Cumberland Pharmaceuticals Inc., Vanderbilt University, LaunchTN, and Gloria Pharmaceuticals. The mission of CET is to bring biomedical technologies and products conceived at Vanderbilt University and other regional research centers to the marketplace. CET helps manage the development and commercialization process for select projects and provides expertise on intellectual property, regulatory, manufacturing and marketing issues that are critical to successful new biomedical products. CET's Life Sciences Center, located in Nashville, Tennessee, provides laboratory space, equipment, and infrastructure to early-stage life sciences companies.